Special Issue

Alphaviruses

Message from the Guest Editor

I am putting together a Special Issue entitled *Alphaviruses*. I would like to publish reviews or short articles written by yourself or your current or former post-doctoral fellows, students, or collaborators in this Special Issue. I would like to feature your most recent work and reviews on the following:

- Small molecule therapeutics, drug discovery, and medicinal chemistry;
- Antivirals, vaccines, and antibodies;
- Animal models:
- Detection methods, imaging methods, biosurveillance, and clinical isolates;
- Viroinformatics;
- Blood-brain barrier (BBB);
- Host-pathogen interactions;
- Effects on neurons, inflammation, and cytopathic effects;
- Structural biology;
- Enzymes.

I would like to highlight some of the more neglected areas of alphaviruses such as understanding their viral code, sequence-to-symptom patterns, host-pathogen interactions, therapeutic strategies, and even some modern methods of research such as machine learning and sequence analysis (viroinformatics) in order to inspire younger generations to pursue work in virology and to recognize that there are still challenging problems ahead.

Guest Editor

Dr. Patricia M. Legler

Center for Biomolecular Science and Engineering, Naval Research Laboratory, Washington, DC 20375, USA

Deadline for manuscript submissions

closed (25 March 2023)



Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



mdpi.com/si/115401

Viruses
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
viruses@mdpi.com

mdpi.com/journal/ viruses





Viruses

an Open Access Journal by MDPI

Impact Factor 3.5 CiteScore 7.7 Indexed in PubMed



About the Journal

Message from the Editor-in-Chief

You are invited to contribute a research article or a comprehensive review for consideration and publication in *Viruses* (ISSN 1999-4915). *Viruses* is published in open access format—research articles, reviews and other content are released on the internet immediately after acceptance. The scientific community and the general public have unlimited free access to the content as soon as it is published. As an open access journal, *Viruses* is supported by the authors or their institutes by payment of article processing charges (APC) for accepted papers. We would be pleased to welcome you as one of our authors.

Editor-in-Chief

Dr. Eric O. Freed

HIV Dynamics and Replication Program, Center for Cancer Research, National Cancer Institute, Frederick, MD 21702-1201, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, MEDLINE, PMC, Embase, PubAg, and other databases.

Journal Rank:

JCR - Q2 (Virology) / CiteScore - Q1 (Virology/Infectious Diseases)

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 18.6 days after submission; acceptance to publication is undertaken in 2.5 days (median values for papers published in this journal in the first half of 2025).

